Investors

MolMed: submitted the utilisation request concerning the first tranche of the capital increase to be reserved to Société Générale pursuant to the agreement named “SEF - Standby Equity Facility” Pdf
MolMed: submitted the utilisation request concerning the first tranche of the capital increase to be reserved to Société Générale pursuant to the agreement named “SEF - Standby Equity Facility” Pdf ▾

Investors

MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 46,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility”
MolMed Board of Directors exercises the power to carry out the capital increase to be reserved to Société Générale of up to no. 46,000,000 ordinary shares pursuant to the agreement named “SEF - Standby Equity Facility” ▾

Investors

Presented at ASCO data on the first patients treated with TK in the Ph III study: survival benefit exceeds trial target
Presented at ASCO data on the first patients treated with TK in the Ph III study: survival benefit exceeds trial target ▾

Investors

New data presented at ASCO on NGR-hTNF: significantly extended survival in mesothelioma and in sarcomas
New data presented at ASCO on NGR-hTNF: significantly extended survival in mesothelioma and in sarcomas ▾

News & Events

Stay update
50th ASCO Annual Meeting ▾

50th ASCO Annual Meeting

Location: Chicago,Illinois

MolMed at this event: posters presentation